Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS t
(Financial Post, 2025-10-13T20:09:45Z)